Click here to stream the public defence
Due to copyright issues, an electronic copy of the thesis must be ordered from the faculty. For the faculty to have time to process the order, the order must be received by the faculty at the latest 2 days before the public defence. Orders received later than 2 days before the defence will not be processed. After the public defence, please address any inquiries regarding the thesis to the candidate.
Trial Lecture – time and place
See Trial Lecture.
Adjudication committee
- First opponent: Associate Professor Harald T. Jørstad, Amsterdam UMC - University of Amsterdam, the Netherlands
- Second opponent: Associate Professor Elisabeth Kleivhaug Vesterbekkmo, NTNU: Norwegian University of Science and Technology
- Third member and chair of the evaluation committee: Professor II Erik Harald Øie, University of Oslo
Chair of the Defence
Associate Professor Lars Fjellbirkeland, University of Oslo
Principal Supervisor
Vibeke Marie Almaas, Consultant Cardiologist, Oslo University Hospital
Summary
Use of anabolic-androgenic steroids (AAS) is a growing public health concern, particularly among young males. Although AAS use has long been suspected to cause adverse cardiovascular effects, relatively few studies have investigated this association. This thesis investigates the effects of long-term anabolic-androgenic steroid (AAS) use on cardiac structure and function in male weightlifters. Participants underwent cardiac assessment using echocardiography and electrocardiography (ECG), along with hormonal analyses of blood and urine samples.
Compared with weightlifters with no history of AAS (weightlifting controls, WLC), AAS users demonstrated increased left ventricular wall thicknesses and reduced systolic function. 10% of AAS users had severely reduced left ventricular systolic function. A longitudinal follow-up study conducted five to seven years after baseline, showed that despite an almost 50% reduction in reported weekly AAS dosage, participants who continued AAS use demonstrated persistent impaired systolic function, along with worsening of diastolic function. In contrast, former users who had discontinued AAS for an average of 11 years, showed near-normalization of cardiac structure and function. A separate study investigated whether ECG could serve as a screening tool for detecting left ventricular hypertrophy in this population. The findings demonstrated that ECG had limited ability to identify these changes.
In conclusion, this thesis demonstrates that long-term AAS use is associated with substantial adverse cardiac remodeling and left ventricular systolic dysfunction. Continued use may sustain these changes even at reduced doses, whereas cessation may be associated with reversibility of cardiac dysfunction.
Additional information
Contact the research support staff.